Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma Journal Article
| Authors: | Markman, M.; Rothman, R.; Hakes, T.; Reichman, B.; Lewis, J. L. Jr; Rubin, S.; Jones, W.; Almadrones, L.; Hoskins, W. |
| Article Title: | Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma |
| Abstract: | While the acute toxicity of cisplatin on renal function is well described, the long-term effects have received little attention in the medical literature. In an effort to examine this important issue, we evaluated the renal function of a group of 60 women with ovarian cancer who received a second-line cisplatin-based chemotherapy program at the Memorial Sloan-Kettering Cancer Center longer than 6 months following the completion of their initial cisplatin-based chemotherapeutic regimen. These patients had not received any cisplatin for a median of 19 months (range, 6-57 months) prior to beginning the second-line program. Only 4 patients (7%) had a serum creatinine value >1.3 mg/dl (upper limit of normal in our laboratory) at the time of initiation of the second-line program. In each case, the serum creatinine was ≤1.6 mg/dl. An additional 6 patients (10%) had a >50% increase in serum creatinine above the initial baseline value prior to any treatment, but were still within the normal range. Following second-line cisplatin therapy, only 1 of the 60 patients (2%) experienced a serum creatinine rise to >2.0 mg/dl. We conclude that a limited number of patients with ovarian cancer who are long-term survivors following cisplatin-based chemotherapy exhibit evidence of a mild persistent compromise of renal function and, in general, second-line cisplatin can be administered to previously treated patients without the development of serious renal dysfunction. © 1991. |
| Keywords: | adult; aged; major clinical study; cisplatin; chemotherapy; ovarian neoplasms; nephrotoxicity; dose-response relationship, drug; time factors; kidney; kidney function; ovary carcinoma; creatine; middle age; human; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s. |
| Journal Title: | Gynecologic Oncology |
| Volume: | 41 |
| Issue: | 3 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1991-06-01 |
| Start Page: | 217 |
| End Page: | 219 |
| Language: | English |
| DOI: | 10.1016/0090-8258(91)90311-r |
| PUBMED: | 1869097 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 27 September 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work